Clinical Trial Update: A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. [EARLY_Phase 1]

View source ↗

Summary

Phase 1 study evaluating anti-CD19/BCMA universal CAR-T cell therapy RD06-05 in autoimmune diseases; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Glomerulonephritis
• Anca-associated Vasculitis
• Anti-gbm Disease
• Idiopathic Inflammatory Myopathy
• Lupus Nephritis
• Membranous Nephropathy
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• RD06-05

Snippet

Sponsor: Nanjing Bioheng Biotech Co., Ltd. | Conditions: SLE, LN | EARLY_Phase 1 | Status: RECRUITING